{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:34:26Z","timestamp":1787020466065,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Henan medical science and technology project jointly built by the ministry and the province","award":["SB201904011"],"award-info":[{"award-number":["SB201904011"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31401071"],"award-info":[{"award-number":["31401071"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Familial progressive hyper- and hypopigmentation (FPHH, MIM 145250) is a rare hereditary skin disorder that is predominantly characterized by progressive, diffuse, partly blotchy hyperpigmented lesions intermingled with scattered hypopigmented spots, lentigines and sometimes Cafe-au-lait spots (CALs). Heterozygous mutations of the KIT ligand (\n                      <jats:italic>KITLG<\/jats:italic>\n                      , MIM 184745) gene are responsible for FPHH. To date, only eight\n                      <jats:italic>KITLG<\/jats:italic>\n                      mutations have been reported to be associated with FPHH, and no clear genotype\u2013phenotype correlations have been established. This study aimed to identify the causative mutations in the\n                      <jats:italic>KITLG<\/jats:italic>\n                      gene in two Chinese FPHH patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Direct sequencing of the coding regions of\n                      <jats:italic>KITLG<\/jats:italic>\n                      was performed. Pathogenicity prediction was performed using bioinformatics tools, including SIFT, Polyphen2, and SWISS-MODEL, and the results were further evaluated according to the 2015 American College of Medical Genetics and Genomics (ACMG) guidelines.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The novel mutation c.104A\u2009&gt;\u2009T (p.Asn35Ile) and the recurrent mutation c.101C\u2009&gt;\u2009T (p.Thr34Ile) in\n                      <jats:italic>KITLG<\/jats:italic>\n                      were identified. As shown using SIFT and Polyphen-2 software, both mutations identified in this study were predicted to be detrimental variations. Three-dimensional protein structure modeling indicated that the mutant KITLG proteins might affect the affinity of KITLG for its receptor, c-KIT. According to the 2015 ACMG guidelines, the novel mutation c.104A\u2009&gt;\u2009T was \u2018likely pathogenic\u2019.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      To date, most of the identified\n                      <jats:italic>KITLG<\/jats:italic>\n                      mutations have been clustered within the conserved VTNNV motif (amino acids 33\u201337) in exon 2. The known mutations are only involved in 33\u00a0V, 34\u00a0T, 36\u00a0N, and 37\u00a0V but not 35\u00a0N. We have now identified a novel mutation in\n                      <jats:italic>KITLG<\/jats:italic>\n                      , c.104A\u2009&gt;\u2009T, that was first reported in FPHH within the conserved 35\u00a0N motif. These results strengthen our understanding of FPHH and expand the mutational spectrum of the\n                      <jats:italic>KITLG<\/jats:italic>\n                      gene.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12920-020-00851-5","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T16:03:31Z","timestamp":1609949011000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Identification of a novel mutation in the KITLG gene in a Chinese family with familial progressive hyper- and hypopigmentation"],"prefix":"10.1186","volume":"14","author":[{"given":"Jianbo","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weisheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naihui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingliu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoumin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenlu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziliang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6414-368X","authenticated-orcid":false,"given":"Miao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"key":"851_CR1","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1001\/archderm.1971.04000180007002","volume":"103","author":"ME Chernosky","year":"1971","unstructured":"Chernosky ME, Anderson DE, Chang JP, Shaw MW, Romsdahl MM. Familial progressive hyperpigmentation. Arch Dermatol. 1971;103:581\u201391.","journal-title":"Arch Dermatol"},{"key":"851_CR2","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1111\/jdv.15968","volume":"34","author":"D Gulseren","year":"2020","unstructured":"Gulseren D, Guleray N, Akgun-Dogan O, Simsek-Kiper PO, Utine EG, Alikasifoglu M, et al. Cafe noir spots: a feature of familial progressive hyper- and hypopigmentation. J Eur Acad Dermatol Venereol. 2020;34:e76\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"851_CR3","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ajhg.2009.03.019","volume":"84","author":"ZQ Wang","year":"2009","unstructured":"Wang ZQ, Si L, Tang Q, Lin D, Fu ZJ, Zhang J, et al. Gain-of-function mutation of KIT ligand on melanin synthesis causes familial progressive hyperpigmentation. Am J Hum Genet. 2009;84:672\u20137.","journal-title":"Am J Hum Genet"},{"key":"851_CR4","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1046\/j.1523-1747.1998.00272.x","volume":"111","author":"JM Grichnik","year":"1998","unstructured":"Grichnik JM, Burch JA, Burchette J, Shea CR. The SCF\/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis. J Invest Dermatol. 1998;111:233\u20138.","journal-title":"J Invest Dermatol"},{"key":"851_CR5","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/jid.2011.29","volume":"131","author":"M Amyere","year":"2011","unstructured":"Amyere M, Vogt T, Hoo J, Brandrup F, Bygum A, Boon L, et al. KITLG mutations cause familial progressive hyper- and hypopigmentation. J Invest Dermatol. 2011;131:1234\u20139.","journal-title":"J Invest Dermatol"},{"key":"851_CR6","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/ced.12702","volume":"40","author":"A Cuell","year":"2015","unstructured":"Cuell A, Bansal N, Cole T, Kaur MR, Lee J, Loffeld A, et al. Familial progressive hyper- and hypopigmentation and malignancy in two families with new mutations in KITLG. Clin Exp Dermatol. 2015;40:860\u20134.","journal-title":"Clin Exp Dermatol"},{"key":"851_CR7","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1111\/bjd.14694","volume":"175","author":"J Zhang","year":"2016","unstructured":"Zhang J, Cheng R, Liang J, Ni C, Li M, Yao Z. Report of a child with sporadic familial progressive hyper- and hypopigmentation caused by a novel KITLG mutation. Br J Dermatol. 2016;175:1369\u201371.","journal-title":"Br J Dermatol"},{"key":"851_CR8","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1590\/abd1806-4841.20175567","volume":"92","author":"XK Fang","year":"2017","unstructured":"Fang XK, He YX, Li YJ, Chen LR, Wang HP, Sun Q. Familial progressive hyper- and hypopigmentation: a report on a Chinese family and evidence for genetic heterogeneity. An Bras Dermatol. 2017;92:329\u201333.","journal-title":"An Bras Dermatol"},{"key":"851_CR9","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/ced.12923","volume":"41","author":"L Zeng","year":"2016","unstructured":"Zeng L, Zheng XD, Liu LH, Fu LY, Zuo XB, Chen G, et al. Familial progressive hyperpigmentation and hypopigmentation without KITLG mutation. Clin Exp Dermatol. 2016;41:927\u20139.","journal-title":"Clin Exp Dermatol"},{"key":"851_CR10","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1111\/j.1365-2133.2009.09428.x","volume":"161","author":"A V\u00e9lez","year":"2009","unstructured":"V\u00e9lez A, Salido R, Amorrich-Campos V, Garnacho-Saucedo G, Alvarez-L\u00f3pez MA, Gal\u00e1n M, et al. Hereditary congenital hypopigmented and hyperpigmented macules (Westerhof syndrome) in two siblings. Br J Dermatol. 2009;161:1399\u2013400.","journal-title":"Br J Dermatol"},{"key":"851_CR11","doi-asserted-by":"publisher","first-page":"350","DOI":"10.4103\/0378-6323.95453","volume":"78","author":"RZ Zhang","year":"2012","unstructured":"Zhang RZ, Zhu WY. Familial progressive hypo- and hyperpigmentation: a variant case. Indian J Dermatol Venereol Leprol. 2012;78:350\u20133.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"851_CR12","doi-asserted-by":"crossref","unstructured":"Zazo Seco C, Serrao de Castro L, van Nierop JW, Morin M, Jhangiani S, Verver EJ, et al. Allelic mutations of KITLG, encoding KIT ligand, cause asymmetric and unilateral hearing loss and waardenburg syndrome type 2. Am J Hum Genet. 2015;97:647\u201360.","DOI":"10.1016\/j.ajhg.2015.09.011"},{"key":"851_CR13","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/pcmr.12597","volume":"30","author":"Y Ogawa","year":"2017","unstructured":"Ogawa Y, Kono M, Akiyama M. Pigmented macules in Waardenburg syndrome type 2 due to KITLG mutation. Pigment Cell Melanoma Res. 2017;30:501\u20134.","journal-title":"Pigment Cell Melanoma Res"},{"key":"851_CR14","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.jid.2017.01.035","volume":"137","author":"A Sorlin","year":"2017","unstructured":"Sorlin A, Maruani A, Aubriot-Lorton MH, Kuentz P, Duffourd Y, Teysseire S, et al. Mosaicism for a KITLG mutation in linear and whorled nevoid hypermelanosis. J Invest Dermatol. 2017;137:1575\u20138.","journal-title":"J Invest Dermatol"},{"key":"851_CR15","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/1346-8138.15313","volume":"47","author":"M Kato","year":"2020","unstructured":"Kato M, Yagami A, Tsukamoto T, Shinkai Y, Kato T, Kurahashi H. Novel mutation in the KITLG gene in familial progressive hyperpigmentation with or without hypopigmentation. J Dermatol. 2020;47:669\u201372.","journal-title":"J Dermatol"},{"key":"851_CR16","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1242\/dev.115.4.1111","volume":"115","author":"KP Steel","year":"1992","unstructured":"Steel KP, Davidson DR, Jackson IJ. Trp-2\/Dt, a new early melanoblast marker, shows that steel growth-factor (C-Kit Ligand) is a survival factor. Development. 1992;115:1111\u20139.","journal-title":"Development"},{"key":"851_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.0022-202x.2001.00006.x","volume":"6","author":"H Yoshida","year":"2001","unstructured":"Yoshida H, Kunisada T, Grimm T, Nishimura EK, Nishioka E, Nishikawa SI. Review: melanocyte migration and survival controlled by SCF\/c-kit expression. J Investig Dermatol Symp Proc. 2001;6:1\u20135.","journal-title":"J Investig Dermatol Symp Proc"},{"key":"851_CR18","doi-asserted-by":"publisher","first-page":"137S","DOI":"10.1038\/jid.1994.25","volume":"103","author":"RA Spritz","year":"1994","unstructured":"Spritz RA. Molecular basis of human piebaldism. J Invest Dermatol. 1994;103:137S-S140.","journal-title":"J Invest Dermatol"},{"key":"851_CR19","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1095\/biolreprod.105.042846","volume":"73","author":"A Mahakali Zama","year":"2005","unstructured":"Mahakali Zama A, Hudson FP 3rd, Bedell MA. Analysis of hypomorphic KitlSl mutants suggests different requirements for KITL in proliferation and migration of mouse primordial germ cells. Biol Reprod. 2005;73:639\u201347.","journal-title":"Biol Reprod"},{"key":"851_CR20","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/genetics\/162.1.331","volume":"162","author":"S Rajaraman","year":"2002","unstructured":"Rajaraman S, Davis W, Mahakali-Zama A, Evans H, Russell L, Bedell M. An allelic series of mutations in the Kit ligand gene of mice. I. Identification of point mutations in seven ethylnitrosourea-induced kitlsteel alleles. Genetics. 2002;162:331\u201340.","journal-title":"Genetics"},{"key":"851_CR21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201324.","journal-title":"Genet Med"},{"key":"851_CR22","doi-asserted-by":"crossref","unstructured":"Kiefer F, Arnold K, Kunzli M, Bordoli L, Schwede T. The SWISS-MODEL repository and associated resources. Nucl Acids Res. 2009;37(Database issue):D387\u201392.","DOI":"10.1093\/nar\/gkn750"},{"issue":"W1","key":"851_CR23","doi-asserted-by":"publisher","first-page":"W252","DOI":"10.1093\/nar\/gku340","volume":"42","author":"M Biasini","year":"2014","unstructured":"Biasini M, Bienert S, Waterhouse A, Arnold K, Studer G, Schmidt T, et al. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucl Acids Res. 2014;42(W1):W252\u20138.","journal-title":"Nucl Acids Res"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-020-00851-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12920-020-00851-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-020-00851-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T15:38:56Z","timestamp":1670686736000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-020-00851-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,6]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["851"],"URL":"https:\/\/doi.org\/10.1186\/s12920-020-00851-5","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,6]]},"assertion":[{"value":"18 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) for medical research involving human subjects and was approved by the ethics committee of Henan Provincial People\u2019s Hospital. Written informed consent was obtained from all individuals who participated in this study and from parents on behalf of minors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of identifying images or other personal or clinical details was obtained from all of the participants or the parents of any participant under the age of 18.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}